Clinical trial
A Multi-country Time and Motion Study to Describe the Experience of Clinicians, Patients and Their Caregivers During the Treatment of Fabry Disease With Enzyme Replacement Therapy With Agalsidase Alfa and Agalsidase Beta
NCT04281537 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-country Time and Motion Study to Describe the Experience of Clinicians, Patients and Their Caregivers During the Treatment of Fabry Disease With Enzyme Replacement Therapy With Agalsidase Alfa and Agalsidase Beta
- Lead sponsor
- Amicus Therapeutics
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 1, 2020
- Completion date
- May 18, 2022
- Enrollment
- 82 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.